Support legislation to reduce unnecessary animal testing for drug development by directing the FDA to fully implement relevant provisions.

Earl L. "Buddy" Carter · Georgia · Republican

policy impact 3.00 specificity 1.00 extraction confidence 92%

Contest this claim

Occurrences

celebrated the House Committee on Energy and Commerce’s passage of the FDA Modernization Act 3.0, a bill directing the U.S. Food and Drug Administration (FDA) to fully implement provisions to reduce unnecessary animal testing for drug development

Carter backed legislation to reduce unnecessary animal testing in drug development by requiring FDA implementation of the bill’s provisions.

Latest News : U.S. Representative Buddy Carter
primary · press_release · model gpt-5.4-mini

Evidence

Wired reports that the FDA Modernization Act 2.0, signed in December 2022, ended the long-standing federal mandate that experimental drugs be tested on animals before human trials, and it allows alternatives such as microfluidic chips, tissue models, organoids, and AI-based models.

Congress and the president enacted the core legislative change that reduced unnecessary animal testing for drug development.

delivered later_term

The US Just Greenlit High-Tech Alternatives to Animal Testing
secondary · model gpt-5.4-mini · confidence 83%

Contest this evidence item

Axios reports that FDA said it would begin phasing out animal-testing requirements for antibody therapies and other drugs, launch a pilot for monoclonal antibody developers, and move toward AI-based and computer-modeling approaches.

FDA implementation has continued beyond the law, showing the anti-animal-testing policy is being operationalized rather than reversed.

delivered later_term

FDA plans to phase out animal testing requirements
secondary · model gpt-5.4-mini · confidence 79%

Contest this evidence item

Assessments

delivered later_term

Buddy Carter can be credited with delivery because he was not just a bystander to the outcome: he was a cosponsor of the FDA Modernization Act 2.0 in the 117th Congress, materially advancing the legislative effort to allow non-animal alternatives in drug development. The core policy change was enacted in December 2022, and the FDA later moved from statutory change to implementation, announcing on April 10, 2025 that it would begin phasing out animal-testing requirements for monoclonal antibodies and expand use of AI, organoids, and other non-animal methods. Because the promise was to support legislation and push FDA implementation, and both the law and subsequent agency follow-through occurred, this is best scored as delivered with later_term timing.

provider codex_cli · model gpt-5.4 · confidence 90%